Cephalon has been accorded a further six months of patent extension by the FDA for its pediatric sleep disorder treatment medication, Provigil.
Cephlaon had complied with the terms of an explicit written request that entailed the provision of clinical studies data after studying the effects of provigil on pediatric patients.Cephalon has settled the ‘provogil’patent infringement litigation with four generic firms, and under this settlement, each of the four defendants will have a non-exclusive royalty bearing right to market and sell a generic version of Provigil in the US, due to become effective in April 2012.
